DOCSLIB.ORG

Pseudoachondroplasia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pseudoachondroplasia Pseudoachondroplasia Pseudoachondroplasia is a type of short-limbed dwarfism, d. Chronic compression myelopathy secondary to habitual deriving its name from phenotypic similarity to achondropla- atlantoaxial dislocation sia. It is characterized by normal facies, short-limbed dwarfism, 7. Extremities joint laxity, and epiphyseal and metaphyseal abnormalities in a. Bowing of the long bones the growing child. b. Deformities of the lower limbs i. Secondary to ligamentous laxity GENETICS/BASIC DEFECTS ii. Ranging from genu varum (bowed legs), genu valgum (knock knees), and genu recurvatum 1. Inheritance iii. A “wind-swept deformity” (bow-leg on one side a. Pseudoachondroplasia: autosomal dominant with and knock-knee on the other side) complete penetrance c. Markedly shortened hands (without trident configura- b. Pseudoachondroplasia types II: autosomal recessive tion) and feet (small percentage of cases from parental gonadal d. Ulnar deviation of the wrist mosaicism) e. Flexion contractures of the elbow and knees 2. Cause f. Brachydactyly a. Mutations in the gene encoding cartilage oligomeric g. “Telescoping” fingers matrix protein (COMP) on the centromeric region of 8. Joint 19p (19p13.1-p12) a. Lax ligament i. Deletions: Approximately 40–50% of cases of b. Premature osteoarthritis pseudoachondroplasia have deletion mutations c. Contractures of the hips in exon 13 of the COMP gene. 9. Prognosis ii. Specific base substitutions a. Good survival iii. Duplications b. Early arthrosis, notably in the hip and knee joints b. Allelic to multiple epiphyseal dysplasia, which is also c. Possible myelopathy secondary to atlantoaxial dislo- caused by COMP mutations cations c. All mutations associated with pseudoachondroplasia and multiple epiphyseal dysplasia: found in exons DIAGNOSTIC INVESTIGATIONS encoding the type III repeat region or C-terminal domain of COMP 1. Radiography d. Mutations in extracellular matrix proteins, COMP, a. Tubular bones types II and IX collagens, and matrilin-3 i. Irregularities and fragmentations of the develop- i. Producing a spectrum of mild to severe chon- ing epiphyses drodysplasias characterized by epiphyseal and ii. Shortened tubular bones vertebral abnormalities iii. Brachydactyly ii. Disruption of protein processing and excessive iv. Delayed epiphyseal ossification (delayed bone age) accumulation of some of these proteins in the v. Small phalangeal epiphyses (miniepiphyses) rough endoplasmic reticulum that appears to vi. Small, irregular carpal bones compromise cellular function vii. Irregular, widened (frayed), mushroomed meta- physes viii. Coxa vara CLINICAL FEATURES b. Pelvis 1. Normal at birth i. Delayed ossification of the capital femoral epi- 2. Normal intelligence physes, which become flattened and small when 3. Normal craniofacial appearance ossified 4. Waddling gait and diminished linear growth at about 2 ii. Commonly observed sclerosis and irregularity of years of age the acetabular roof 5. Rhizomelic short-limbed dwarfism c. Vertebrae a. Body proportion resembling achondroplasia i. Characteristic anterior beaking or tonguing (in b. Usually detectable at age 2–4 years lateral view of the lumbar spines) 6. Spine a) Due to delayed ossification of the annular a. Accentuated lumbar lordosis epiphyses b. Scoliosis b) Vertebrae becoming more normal in appear- c. Kyphosis ance after puberty 826 PSEUDOACHONDROPLASIA 827 i. Characteristic platyspondyly in childhood Briggs MD, Rasmussen IM, Weber JL, et al.: Genetic linkage of mild pseudoa- ii. Kyphoscoliosis chondroplasia (PSACH) to markers in the pericentromeric region of chro- mosome 19. Genomics 18:656–660, 1993. iii. Lumbar lordosis Briggs MD, Mortier GR, Cole WG, et al.: Diverse mutations in the gene for iv. Odontoid hypoplasia cartilage oligomeric matrix protein in the pseudoachondroplasia-multiple v. Atlantoaxial dislocations epiphyseal dysplasia disease spectrum. Am J Hum Genet 62:311–319, d. Ribs: spatulate 1998. 2. Histology of growth plates Briggs MD, Chapman KL: Pseudoachondroplasia and multiple epiphyseal dys- plasia: mutation review, molecular interactions, and genotype to pheno- a. Irregular arrangement of chondrocytes without col- type correlations. Hum Mutat 19:465–478, 2002. umn formation Byers PH: Molecular heterogeneity in chondrodysplasias. (Editorial) Am J b. Irregular provisional calcification Hum Genet 45:1–4, 1989. c. Intracytoplasmic inclusions in chondrocytes Cohn DH, Briggs MD, King LM, et al.: Mutations in the cartilage 3. EM of chondrocytes oligomeric matrix protein (COMP) gene in pseudoachondroplasia and multiple epiphyseal dysplasia. Ann N Y Acad Sci 785:188–194, a. Showing distinctive giant rough endoplasmic reticu- 1996. lum cisternae filled with punctuate material Cooper RR, Ponseti IV, Maynard JA: Pseudoachondroplastic dwarfism. A b. The material composed of alternating electron-lucent and rough-surfaced endoplasmic reticulum storage disorder. J Bone Joint electron-dense layers in a unique lamellar appearance Surg 55A:475–484, 1973. 4. Molecular diagnosis Cranley RE, Williams BR, Kopits SE, et al.: Pseudoachondroplastic dyspla- sia: five cases representing clinical, roentgenographic and histologic a. Techniques heterogeneity. Birth Defects Original Article Series 11(6):205–215, i. Mutation screening in exons of the COMP gene 1975. using SSCP and sequence analysis Deere M, Sanford T, Ferguson HL, et al.: Identification of twelve muta- ii. COMP mutation screening in RNA isolated from tions in cartilage oligomeric matrix protein (COMP) in patients with pseudoachondroplasia. Am J Med Genet 80:510–513, skin fibroblast cell line 1998. b. Particularly useful in adult patients where radiologi- Dennis NR, Renton P: The severe recessive form of pseudoachondroplasia. cal diagnosis can be difficult Pediatr Radiol 3:169–175, 1975. Ferguson Hl, Deere M, Evans R, et al.: Mosaicism in pseudoachondroplasia. GENETIC COUNSELING Am J Med Genet 70:287–201, 1997. Hall JG: Pseudoachondroplasia. Birth Defects Orig Artic Ser 11:187–202, 1. Recurrence risk 1975. a. Autosomal dominant inheritance Hall JG, Dorst JP: Pseudoachondroplastic SED, recessive Maroteaux-Lamy i. Patient’s sibs type. Birth Defects Orig Art Ser V(4):254–259, 1969. a) 50% if one of the parent is affected Hall JG, Dorst JP, Rotta J, McKusick VA: Gonadal mosaicism in pseudoachon- droplasia. Am J Med Genet 28:143–151, 1987. b) Not increased if parents are normal Hecht JT, Nelson LD, Crowder E et al.: Mutations in exon 17B of cartilage ii. Patient’s offspring: 50% oligomeric matrix protein (COMP) cause pseudoachondroplasia. Nature b. Autosomal recessive inheritance Genet 10:325–329, 1995. i. Patient’s sibs Heselson NG, Cremin BJ, Beighton P: Pseudoachondroplasia: a report of 13 cases. Brit J Radiol 59:473–482, 1977. a) 25% for true autosomal recessive inheritance Ikegawa S, Ohashi H, Nishimura G, et al.: Novel and recurrent COMP (car- b) Slightly increased risk in case of parental tilage oligomeric matrix protein) mutations in pseudoachondroplasia gonadal mosaicism (depending on the degree and multiple metaphyseal dysplasia. Hum Genet 103:633–638, of mosaicism) 1998. ii. Patient’s offspring: not increased unless the Kopits SE, Lindstrom JA, McKusick VA: Pseudoachondroplastic dysplasia: pathodynamics and management. In: Bergsma D (ed.): Skeletal spouse is also carrying the gene Dysplasias. Amsterdam: Excerpta Medica (pub.) 1974, pp 341–| 2. Prenatal diagnosis 352. a. Prenatal ultrasonography unlikely to detect the skele- Langer LO Jr, Schaefer GB, Wadsworth DT: Patient with double heterozygos- tal changes, which will not manifest until about 2 ity for achondroplasia and pseudoachondroplasia, with comments on years of age these conditions and the relationship between pseudoachondroplasia and multiple epiphyseal dysplasia, Fairbank type. Am J Med Genet 47: b. Prenatal diagnosis possible in the family at risk and 772–781, 1993. the disease-causing COMP mutation has been charac- Maroteaux P, Stanescu R, Stanescu V, et al.: The mild form of pseudoachon- terized in an affected individual droplasia. Eur J Pediatr 133:227–231, 1980. 3. Management McKeand J, Rotta J, Hecht JT: Natural history study of pseudoachondroplasia. Am J Med Genet 63:406–410, 1996. a. Supportive Newman B, Donnah D, Briggs MD: Molecular diagnosis is important to b. Surgical correction of the leg deformities confirm suspected pseudoachondroplasia. J Med Genet 37:64–65, c. Hip replacement for severe hip contractures 2000. d. Cervical stabilization procedures for cervical cord com- Song HR, Lee KS, Li QW, et al.: Identification of cartilage oligomeric pression with progressive neurologic symptoms and signs matrix protein (COMP) gene mutations in patients with pseudoachon- droplasia and multiple epiphyseal dysplasia. J Hum Genet 48:222–225, 2003. REFERENCES Wynne-Davis R, Hall CM, Young ID: Pseudoachondroplasia: clinical diagnosis Beck M, Lingnau K, Spranger J: Newly synthesized proteoglycans in pseudoa- at different ages and comparison of autosomal dominant and recessive chondroplasia. Bone 9:367–370, 1988. types: a review of 32 patients (26 kindreds). J Med Genet 23:425–434, Briggs MD, Hoffman SMG, King LM, et al.: Pseudoachondroplasia and mul- 1986. tiple epiphyseal dysplasia due to mutations in the cartilage oligomeric Young ID, Moore JR: Severe pseudoachondroplasia with parental consanguinity. matrix protein gene. Nature Genet 10:330–336, 1995. J Med Genet 22:150, 1985. 828 PSEUDOACHONDROPLASIA Fig. 1. A girl with pseudoachondroplasia at 2 and half years (upper) with normal craniofacial appearance, mild short
Load more

Recommended publications
  • Serum Or Plasma Cartilage Oligomeric Matrix Protein Concentration As a Diagnostic Marker in Pseudoachondroplasia: Differential Diagnosis of a Family
    European Journal of Human Genetics (2007) 15, 1023–1028 & 2007 Nature Publishing Group All rights reserved 1018-4813/07 $30.00 www.nature.com/ejhg ARTICLE Serum or plasma cartilage oligomeric matrix protein concentration as a diagnostic marker in pseudoachondroplasia: differential diagnosis of a family A Cevik Tufan*,1,2,7, N Lale Satiroglu-Tufan2,3,7, Gail C Jackson4, C Nur Semerci3, Savas Solak5 and Baki Yagci6 1Department of Histology and Embryology, School of Medicine, Pamukkale University, Denizli, Turkey; 2Pamukkale University Research Center for Genetic Engineering and Biotechnology, Denizli, Turkey; 3Molecular Genetics Laboratory, Department of Medical Biology, Center for Genetic Diagnosis, School of Medicine, Pamukkale University, Denizli, Turkey; 4NGRL, St Mary’s Hospital, Manchester, UK; 5Birgi Medical Center, Republic of Turkey Ministry of Health, Izmir, Turkey; 6Department of Radiology, School of Medicine, Pamukkale University, Denizli, Turkey Pseudoachondroplasia (PSACH) is an autosomal-dominant osteochondrodysplasia due to mutations in the gene encoding cartilage oligomeric matrix protein (COMP). Clinical diagnosis of PSACH is based primarily on family history, physical examination, and radiographic evaluation, and is sometimes extremely difficult, particularly in adult patients. Genetic diagnosis based on DNA sequencing, on the other hand, can be expensive, time-consuming, and intensive because COMP mutations may be scattered throughout the gene. However, there is evidence that decreased plasma COMP concentration may serve as a diagnostic marker in PSACH, particularly in adult patients. Here, we report the serum and/or plasma COMP concentration-based differential diagnosis of a family with affected adult members. The mean serum and/or plasma COMP concentrations of the three affected family members alive (0.6970.15 and/or 0.8170.08 lg/ml, respectively) were significantly lower than those of an age-compatible control group of 21 adults (1.5270.37 and/or 1.3770.36 lg/ml, respectively; Po0.0001).
    [Show full text]
  • Essential Genetics 5
    Essential genetics 5 Disease map on chromosomes 例 Gaucher disease 単一遺伝子病 天使病院 Prader-Willi syndrome 隣接遺伝子症候群，欠失が主因となる疾患 臨床遺伝診療室 外木秀文 Trisomy 13 複数の遺伝子の重複によって起こる疾患 挿画 Koromo 遺伝子の座位あるいは欠失等の範囲を示す Copyright (c) 2010 Social Medical Corporation BOKOI All Rights Reserved. Disease map on chromosome 1 Gaucher disease Chromosome 1q21.1 1p36 deletion syndrome deletion syndrome Adrenoleukodystrophy, neonatal Cardiomyopathy, dilated, 1A Zellweger syndrome Charcot-Marie-Tooth disease Emery-Dreifuss muscular Hypercholesterolemia, familial dystrophy Hutchinson-Gilford progeria Ehlers-Danlos syndrome, type VI Muscular dystrophy, limb-girdle type Congenital disorder of Insensitivity to pain, congenital, glycosylation, type Ic with anhidrosis Diamond-Blackfan anemia 6 Charcot-Marie-Tooth disease Dejerine-Sottas syndrome Marshall syndrome Stickler syndrome, type II Chronic granulomatous disease due to deficiency of NCF-2 Alagille syndrome 2 Copyright (c) 2010 Social Medical Corporation BOKOI All Rights Reserved. Disease map on chromosome 2 Epiphyseal dysplasia, multiple Spondyloepimetaphyseal dysplasia Brachydactyly, type D-E, Noonan syndrome Brachydactyly-syndactyly syndrome Peters anomaly Synpolydactyly, type II and V Parkinson disease, familial Leigh syndrome Seizures, benign familial Multiple pterygium syndrome neonatal-infantile Escobar syndrome Ehlers-Danlos syndrome, Brachydactyly, type A1 type I, III, IV Waardenburg syndrome Rhizomelic chondrodysplasia punctata, type 3 Alport syndrome, autosomal recessive Split-hand/foot malformation Crigler-Najjar
    [Show full text]
  • Discover Dysplasias Gene Panel
    Discover Dysplasias Gene Panel Discover Dysplasias tests 109 genes associated with skeletal dysplasias. This list is gathered from various sources, is not designed to be comprehensive, and is provided for reference only. This list is not medical advice and should not be used to make any diagnosis. Refer to lab reports in connection with potential diagnoses. Some genes below may also be associated with non-skeletal dysplasia disorders; those non-skeletal dysplasia disorders are not included on this list. Skeletal Disorders Tested Gene Condition(s) Inheritance ACP5 Spondyloenchondrodysplasia with immune dysregulation (SED) AR ADAMTS10 Weill-Marchesani syndrome (WMS) AR AGPS Rhizomelic chondrodysplasia punctata type 3 (RCDP) AR ALPL Hypophosphatasia AD/AR ANKH Craniometaphyseal dysplasia (CMD) AD Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy ARSB syndrome AR ARSE Chondrodysplasia punctata XLR Spondyloepimetaphyseal dysplasia with joint laxity type 1 (SEMDJL1) B3GALT6 Ehlers-Danlos syndrome progeroid type 2 (EDSP2) AR Multiple joint dislocations, short stature and craniofacial dysmorphism with B3GAT3 or without congenital heart defects (JDSCD) AR Spondyloepimetaphyseal dysplasia (SEMD) Thoracic aortic aneurysm and dissection (TADD), with or without additional BGN features, also known as Meester-Loeys syndrome XL Short stature, facial dysmorphism, and skeletal anomalies with or without BMP2 cardiac anomalies AD Acromesomelic dysplasia AR Brachydactyly type A2 AD BMPR1B Brachydactyly type A1 AD Desbuquois dysplasia CANT1 Multiple epiphyseal dysplasia (MED) AR CDC45 Meier-Gorlin syndrome AR This list is gathered from various sources, is not designed to be comprehensive, and is provided for reference only. This list is not medical advice and should not be used to make any diagnosis.
    [Show full text]
  • Pseudoachondroplasia and Multiple Epiphyseal Dysplasia
    RESEARCH ARTICLE OFFICIAL JOURNAL Pseudoachondroplasia and Multiple Epiphyseal Dysplasia: A 7-Year Comprehensive Analysis of the Known www.hgvs.org Disease Genes Identify Novel and Recurrent Mutations and Provides an Accurate Assessment of Their Relative Contribution Gail C. Jackson,1,2† Laureane Mittaz-Crettol,3† Jacqueline A. Taylor,1 Geert R. Mortier,4 Juergen Spranger,5 Bernhard Zabel,5 Martine Le Merrer,6 Valerie Cormier-Daire,6 Christine M. Hall,7 Amaka Offiah,8 Michael J. Wright,9 Ravi Savarirayan,10 Gen Nishimura,11 Simon C. Ramsden,2 Rob Elles,2 Luisa Bonafe,3 Andrea Superti-Furga,3 Sheila Unger,3 Andreas Zankl,12 and Michael D. Briggs1∗ 1Wellcome Trust Centre for Cell Matrix Research, University of Manchester, Manchester, United Kingdom; 2National Genetics Reference Laboratory, Manchester, United Kingdom; 3Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 4Department of Medical Genetics, Antwerp University Hospital, Antwerp, Belgium; 5Institute for Human Genetics and Center for Paediatrics and Adolescent Medicine, Freiburg, Germany; 6Hopitalˆ Necker-Enfants Malades, Paris, France; 7Great Ormond Street Hospital for Children, London, United Kingdom; 8Sheffield Children’s Hospital, Sheffield, United Kingdom; 9Institute of Human Genetics, Newcastle-upon-Tyne, United Kingdom; 10Murdoch Children’s Research Institute, Genetic Health Services Victoria and Department of Paediatrics, University of Melbourne, Melbourne, Australia; 11Department of Paediatric Imaging, Tokyo Metropolitan Children’s Medical Centre, Japan; 12Bone Dysplasia Research Group, University of Queensland Centre for Clinical Research, University of Queensland, Brisbane, Australia Communicated by David Rimoin Received 7 July 2011; accepted revised manuscript 29 August 2011. Published online 15 September 2011 in Wiley Online Library (www.wiley.com/humanmutation).DOI: 10.1002/humu.21611 ABSTRACT: Pseudoachondroplasia (PSACH) and mul- ferred to the network prior to mutation analysis.
    [Show full text]
  • Joint Degeneration in a Mouse Model of Pseudoachondroplasia: ER Stress, Inflammation And
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.04.447121; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Joint degeneration in a mouse model of pseudoachondroplasia: ER stress, inflammation and autophagy blockage Jacqueline T. Hecht1, 2, Alka C. Veerisetty1, Mohammad G. Hossain1, Debabrata Patra3, Frankie Chiu1, Francoise Coustry1 and Karen L. Posey1* Department of Pediatrics1 McGovern Medical School, and School of Dentistry2 at The University of Texas Health Science Center at Houston (UTHealth), Houston, 77030 TX, USA, 3Institute of Clinical and Translational Sciences Washington University at St. Louis, St. Louis, 63130 MO, USA To whom correspondence should be sent: Karen Posey, PhD Department of Pediatrics McGovern Medical School UTHealth 6431 Fannin Rm MSB 3.306 Houston, TX 77030 Phone: 713/500-5786 Fax: 713/500-5689 Email: [email protected] *Denotes first and senior author. Key words: Cartilage oligomeric matrix protein, autophagy, ER stress, dwarfism, chondrocyte, articular cartilage, joint degeneration bioRxiv preprint doi: https://doi.org/10.1101/2021.06.04.447121; this version posted June 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Pseudoachondroplasia (PSACH), a short limb skeletal dysplasia, associated with premature joint degeneration is caused by misfolding mutations in cartilage oligomeric matrix protein (COMP). Here, we define mutant-COMP- induced stress mechanisms that occur in articular chondrocytes of MT-COMP mice, a murine model of PSACH.
    [Show full text]
  • A Genetic Approach to the Diagnosis of Skeletal Dysplasia
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH Number 401, pp. 32–38 © 2002 Lippincott Williams & Wilkins, Inc. A Genetic Approach to the Diagnosis of Skeletal Dysplasia Sheila Unger, MD The skeletal dysplasias are a large and hetero- geneous group of disorders. Currently, there Glossary are more than 100 recognized forms of skeletal COL9A1, COL9A2, COL9A3 ϭ Type IX col- dysplasia, which makes arriving at a specific di- lagen is a heterotrimeric protein composed agnosis difficult. This process is additionally of one chain each of ␣1(1ϫ), ␣2(1ϫ), and complicated by the rarity of the individual con- ␣3(1ϫ). These three polypeptides are in turn ditions. The establishment of a precise diagnosis encoded by three separate genes: COL9A1, is important for numerous reasons, including COL9A2, and COL9A3. prediction of adult height, accurate recurrence COMP ϭ The cartilage oligomeric matrix pro- risk, prenatal diagnosis in future pregnancies, tein is a homopentameric structural protein and most importantly, for proper clinical treat- and it is a part of the extracellular matrix of ment. When a child is referred for genetic eval- cartilage. The protein is encoded by the uation of suspected skeletal dysplasia, clinical COMP gene. and radiographic indicators, and more specific DTDST ϭ The DTDST gene codes for the di- biochemical and molecular tests, are used to try astrophic dysplasia sulphate transporter which to arrive at the underlying diagnosis. Prefer- is necessary for the sulfation of proteogly- ably, the clinical features and pattern of radio- cans in the cartilage matrix. graphic abnormalities are used to generate a FGFR3 ϭ The fibroblast growth factor receptor differential diagnosis so that the appropriate 3 is a tyrosine kinase receptor that binds confirmatory tests can be done.
    [Show full text]
  • Clinical and Radiographic Features of Multiple Epiphyseal Dysplasia Not Linked to the COMP Or Type IX Collagen Genes
    European Journal of Human Genetics (2001) 9, 606 ± 612 ã 2001 Nature Publishing Group All rights reserved 1018-4813/01 $15.00 www.nature.com/ejhg ARTICLE Clinical and radiographic features of multiple epiphyseal dysplasia not linked to the COMP or type IX collagen genes Geert R Mortier*1, Kathryn Chapman2, Jules L Leroy1 and Michael D Briggs2 1Department of Medical Genetics, Ghent University Hospital, Ghent, Belgium; 2Wellcome Trust Centre for Cell Matrix Research, Manchester, UK Multiple epiphyseal dysplasia (MED) is a mild chondrodysplasia affecting the structural integrity of cartilage and causing early-onset osteoarthrosis in adulthood. The condition is genetically heterogeneous. Mutations in the COMP gene and in two genes (COL9A2; COL9A3), coding respectively for the a2(IX) and a3(IX) chains of type IX collagen, can cause the autosomal dominant forms of MED. Mutations in the DTDST gene have recently been identified in a recessive form of MED. However, for the majority of MED cases, the genetic defect still remains undetermined. We report a three-generation family with an autosomal dominant form of MED, characterised by normal stature, joint pain in childhood and early-onset osteoarthrosis, affecting mainly the hips and knees. Based on discordant inheritance among affected individuals linkage of the phenotype to the COMP, COL9A1, COL9A2, COL9A3 genes was excluded. Our study provides evidence that at least another locus, distinct from COL9A1, is involved in autosomal dominant MED. European Journal of Human Genetics (2001) 9, 606 ± 612. Keywords: multiple epiphyseal dysplasia; osteochondrodysplasia; skeletal dysplasia; genetic linkage Introduction for the a-chains of type IX collagen (COL9A2; COL9A3) Multiple epiphyseal dysplasia (MED) is a clinically mild were identified in MED patients (EDM2, OMIM#600204; and genetically heterogeneous osteochondrodysplasia.
    [Show full text]
  • Pdf File for Personal Use
    942 LETTER TO JMG J Med Genet: first published as 10.1136/jmg.40.12.942 on 18 December 2003. Downloaded from A recurrent R718W mutation in COMP results in multiple epiphyseal dysplasia with mild myopathy: clinical and pathogenetic overlap with collagen IX mutations E Jakkula, J Lohiniva, A Capone, L Bonafe, M Marti, V Schuster, A Giedion, G Eich, E Boltshauser, L Ala-Kokko, A Superti-Furga ............................................................................................................................... J Med Genet 2003;40:942–948 ultiple epiphyseal dysplasia (MED) is clinically and Key points genetically a heterogeneous disorder that affects growth centres and results in delayed and irregular M 12 mineralisation of the ossification centres. Recessively N A heterozygous R718W mutation in the COMP gene inherited MED (rMED; MIM 226900) accounts for a was ascertained in a three generation family in which significant proportion of MED cases and is associated with two children presented with muscular weakness, a mutations in the sulphate transporter gene, DTDST/ moderate rise in creatine kinase, and knee joint SLC26A2.34 More often, MED is inherited as a dominant epiphyseal dysplasia. The same mutation was identi- trait. Thus far, five different genes have been implicated in fied in a second family with dominantly inherited dominantly inherited MED: the gene for cartilage oligomeric multiple epiphyseal dysplasia (MED) with similar matrix protein, COMP (MIM 600310); the genes for the a1, radiographic changes. a2, and a3 chains of collagen IX, COL9A1 (MIM 120165), N Mild myopathy is not exclusively associated with COL9A2 (MIM 120260), and COL9A3 (MIM 120270); and collagen IX-MED but can occur in COMP-MED as well.
    [Show full text]
  • Pseudoachondroplasia
    Srp Arh Celok Lek. 2013 Sep-Oct;141(9-10):676-679 DOI: 10.2298/SARH1310676R 676 ПРИКАЗ БОЛЕСНИКА / CASE REPORT UDC: 616.7-053.2 Pseudoachondroplasia: A Case Report Vladimir Radlović1, Željko Smoljanić1, Nedeljko Radlović1,2, Miroslav Jakovljević3, Zoran Leković1, Siniša Dučić1,2, Polina Pavićević1,2 1University Children’s Hospital, Belgrade, Serbia; 2School of Medicine, University of Belgrade, Belgrade, Serbia; 3Child and Youth Health Care Institute of Vojvodina, Novi Sad, Serbia SUMMARY Introduction Pseudoachondroplasia (PSACH) is an autosomal dominant osteochondrodysplasia due to mutations in the gene encoding cartilage oligomeric matrix protein. It is characterized by rhizomelic dwarfism, limb and vertebral deformity, joint laxity and early onset osteoarthrosis. We present the girl with the early expressed and severe PSACH born to clinically and radiographically unaffected parents. Case Outline A 6.5-year-old girl presented with short-limbed dwarfism (body height 79.5 cm, <P5; -32%) and normal craniofacial appearance and intelligence. The girl was normal until 3 months of age when she expressed growth retardation with apparently shorter extremities in relation to the torso. With age, her rhizomelic dwarfism became increasingly visible, and since completed 15 months of age, when she started to walk, the disease was complicated with genu varum, lumbar lordosis and abnormal gait. Beside visibly short forearms, short, broad and ulnar deviation of the hands, brachydactyly and joint hyperlaxity, the radiographic picture showed markedly flared metaphyses, small and irregular epiphyses and poorly formed acetabulum. Conclusion PSACH is an achondroplasia-like rhizomelic dwarfism recognized by the absence of abnor- mality at birth, normal craniofacial appearance, characteristic epiphyseal and metaphyseal radiographic finding and joint hyperlaxity.
    [Show full text]
  • Identification of Two Novel Mutations in the COMP Gene in Six Families with Pseudoachondroplasia
    2180 MOLECULAR MEDICINE REPORTS 14: 2180-2186, 2016 Identification of two novel mutations in the COMP gene in six families with pseudoachondroplasia WEI-JIA YU1*, ZENG ZHANG2*, JIN-WEI HE1, WEN-ZHEN FU1, CHUN WANG1 and ZHEN-LIN ZHANG1 1Department of Osteoporosis and Bone Diseases, Metabolic Bone Disease and Genetic Research Unit; 2Department of Orthopedic Surgery, Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200233, P.R. China Received May 31, 2015; Accepted April 13, 2016 DOI: 10.3892/mmr.2016.5486 Abstract. Pseudoachondroplasia (PSACH; MIM no. 177170) resolve with age, however osteoarthritis is progressive and is an autosomal dominant osteochondrodysplasia character- severe. ized by short-limb short stature, brachydactyly and early-onset Previous genetic studies have demonstrated that PSACH is osteoarthropathy. Typically, at approximately two years caused by heterozygous mutations in the cartilage oligomeric of age, the rate of growth falls below the standard growth matrix protein (COMP; MIM no. 600310) gene (2,3). COMP curve, causing a moderately severe form of disproportionate is located on chromosome 19p13.1 (4). COMP rat and bovine short-limb short stature. The current study described the clin- sequencing indicate that it is a member of the thrombospondin ical and radiographic observations of six Chinese patients with gene family (4). It contains 19 exons, encoding the epidermal PSACH, and identified two de novo novel missense mutations growth factor-like (type II) repeats, calmodulin-like (type III) [p.Asp326Asn (c.976G>A) and c.1585A>G (p.Thr529Ala)] in repeats and the C-terminal domain. Exons 4-19 correspond in cartilage oligomeric matrix protein (COMP) in the patients.
    [Show full text]
  • Vitreoretinopathy with Phalangeal Epiphyseal Dysplasia, a Type II
    661 SHORT REPORT J Med Genet: first published as 10.1136/jmg.39.9.661 on 1 September 2002. Downloaded from Vitreoretinopathy with phalangeal epiphyseal dysplasia, a type II collagenopathy resulting from a novel mutation in the C-propeptide region of the molecule A J Richards, J Morgan,PWPBearcroft, E Pickering, M J Owen, P Holmans, N Williams, C Tysoe, F M Pope, M P Snead, H Hughes ............................................................................................................................. J Med Genet 2002;39:661–665 quadrant of some patients. Although the vitreous did not A large family with dominantly inherited rhegmatogenous exhibit the congenital membraneous anomaly characteristic retinal detachment, premature arthropathy, and develop- of Stickler syndrome type 1,15–17 the architecture was strikingly ment of phalangeal epiphyseal dysplasia, resulting in abnormal, with absence of the usual lamellar array. Affected brachydactyly was linked to COL2A1, the gene encoding subjects had a spherical mean refractive error of –1.46 diopt- α pro 1(II) collagen. Mutational analysis of the gene by res (SD 1.5), which was not significantly greater than that in exon sequencing identified a novel mutation in the unaffected subjects (mean refractive error –0.71, SD 0.99, C-propeptide region of the molecule. The glycine to aspar- p=0.13, Mann-Whitney test). The axial length was slightly tic acid change occurred in a region that is highly greater in affected eyes (mean 24.6 mm, SD 0.73) compared conserved in all fibrillar collagen molecules. The resulting with unaffected eyes (mean 23.8 mm, SD 1.1, p=0.008, t test). phenotype does not fit easily into pre-existing subgroups of A single affected subject, whose axial length had increased to the type II collagenopathies, which includes spondyloepi- 33.5 mm, following retinal detachment surgery, distorted any physeal dysplasia, and the Kniest, Strudwick, and Stickler apparent variation in myopia between affected and unaffected dysplasias.
    [Show full text]
  • TEST CATALOGUE October 2020 ACHIEVING a POSITIVE CHANGE
    TEST CATALOGUE October 2020 ACHIEVING A POSITIVE CHANGE ... CENTOGENE IS DEDICATED TO TRANSFORMING THE SCIENCE OF GENETIC INFORMATION INTO SOLUTIONS AND HOPE FOR PATIENTS WITH RARE DISEASES AND THEIR FAMILIES. BOSTON We achieve this by: › Leveraging the world’s largest database in rare genetic disorders with genetic, proteomic, metabolomic, and clinical information – CentoMD® › Applying our knowledge derived from our global diagnostic testing services – addressing the worldwide heterogeneity in ethnicities › Guaranteeing the highest quality in our processes based on the highest level of accreditation OUR GLOBAL FOOTPRINT The outcome of growth and expansion at CENTOGENE is the inauguration of new locations. As a cosmopolitan company, we have a strong international footprint. ROSTOCK HAMBURG BERLIN DELHI FRANKFURT VIENNA DUBAI SOLID GROWTH IN JUST OVER A DECADE Metabolomic Oncogenetic Biomarkers MLPA >180 NGS panels platform testing CentoCard® qPCR Whole exome 2006 The logistic solution sequencing Diagnostics in neurogenetic diseases Non-invasive Carrier > 9,000 Whole genome prenatal testing screening different test sequencing 2016 (CentoNIPT®) (CentoScreen®) assays CentoMD® Proteomic Microarrays High throughput Transcriptomics The mutation platform genomic facility 2018 database iPSC program IPO Artificial Intelligence 2020+ initiative 2019 Providing world-class genetic testing and life-changing solutions for all rare disease patients 2019 WHAT DRIVES CENTOGENE Our goal: providing precise medical diagnosis of inherited diseases at the earliest possible moment; transforming medical expertise and analytical information into actionable results for physicians, patients, and pharmaceutical partners. Our commitment: life-long support for our patients and partners - driven by the continuous improvement of our diagnostic quality and therapeutic options for individual patients. Our work does not end by just delivering a medical diagnosis.
    [Show full text]